Your browser doesn't support javascript.

Portal de Pesquisa da BVS Veterinária

Informação e Conhecimento para a Saúde

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:



Adicionar mais destinatários

Enviar resultado
| |

Pimobendan improves clinical signs in short term compared to digoxin or placebo in dogs with heart failure due to chronic degenerative mitral valve disease

Helena Matiko Akao Larsson, Maria; Saretta Schwartz, Denise; Teixeira Goldfeder, Guilherme; Marinho Costa de Oliveira, Valéria; Hiromi Itikawa, Paula; Marques Mazini, Ariane; Ramos Rosa Melo, Priscylla; Lorenzini Aranha Machado, Fabrício; oncisconcisconcisconcisconcisco; Kazue Kanayama, Khadine; Pellegrino, Arine; Gonçalves Teixeira Daniel, Alexandre; Ossada, Raul.
Acta Sci. vet.; 42: 1-7, 2014.
Artigo em Inglês | VETINDEX-Express | ID: vti-475593


Background: Chronic degenerative mitral valve disease (CDMVD) continues to be the most common cause of heart failure (HF) in small breed dogs. Pimobendan (PIMO) is a mixed action drug with inotropic and vasodilator properties and is widely used to treat heart disease in dogs. Therefore, PIMO increases cardiac output, reduces both preload and afterload and increases myocardial contractility without increasing energy consumption and myocardial oxygen. Digoxin (DIG) is a cardiac glycoside acting through inhibition of the sarcolemmal Na+/K+ ATPase pump, hence increasing intracellular calcium. It exerts beneficial effects on left ventricular function, symptoms and exercise tolerance. The purpose of this prospective, randomized, double blind clinical trial was to evaluate the clinical response and QoLQ in heart failure (HF) dogs treated with digoxin or pimobendan in addition to conventional therapy (furosemide and benazepril).Materials, Methods & Results: Inclusion criteria: dogs in class III or stabilized class IV (NYHA). Exclusion criteria: use of positive inotrope and antiarrhythmic, presence of atrial fibrillation, renal or hepatic disease or neoplasia. Thirty three dogs were included and randomly assigned to DIG (n = 11), PIMO (n = 14) and placebo (PL) (n = 8) and followed up weekly. Data was evaluated for days zero, 7, 14 and 28. Increasing score was assigned to each variab
Biblioteca responsável: BR68.1